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 Brest implants made of materials such as ivory, 
rubber, or ox cartilage have been used since the 
19th century. After the 1940s, direct subcutaneous 
silicone injections were introduced, which caused 
serious complications (infections and migration to 
distant tissues). In the 1960s, a solid silicone en-
velope ﬁlled with silicone gel or saline was used. 
Escape of silicone from the envelope of these im-
plants could be either intracapsular or extracapsu-
lar, penetrating though the ﬁbrous capsule formed 
around the implant. In 1992, the US Food and 
Drug Administration decided that silicone gel-ﬁlled 
implants could only be used in women in clinical 
studies, for revision after unsatisfactory saline im-
plantation, or after mastectomy for breast cancer. 
In contrast, these implants have been regularly 
used for cosmetic purpose in Europe. Autoim-
mune disorders in women with silicone implants 
were reported in the 1970s and 1980s, includ-
ing systemic lupus erythematosus, scleroderma, 
rheumatoid arthritis and some rheumatologic 
conditions (1). Several studies examined the as-
sociation between implants and the development 
of connective tissue disease (CTD), with a relative 
risk of 1.24 for CTD in women silicone breast im-
plants (1-5). In Tel Aviv, ﬁve women with CTD who 
had silicone implants were treated for 18 months 
(1). These ﬁve cases covered a wide spectrum of 
CTDs in women who had silicone implants for peri-
ods of up to 25 years. Two of these ﬁve cases had 
other possible causes of their CTD, i.e. metastatic 
breast cancer in patients with dermatomyositis, or 
drug induction (high doses of paracetamol, met-
amizole, ibuprofen). The diagnoses were: mor-
phea, dermatomyositis, systemic sclerosis, chil-
blain lupus/vasculitis, and eosinophilic fasciitis. In 
patients with ﬁbromyalgia it has been suggested 
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to be related to silicone implants (1). None of the 
patients wanted explanation.
 Because of the multifactorial nature of most 
autoimmune disorders, women seeking breast 
implants should be screened for the known trig-
gers for developing CTD. Until we have better di-
agnostic tools, the women at risk of autoimmune 
diseases should not be considered for implanta-
tion of silicone devices for cosmetic purpose.
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 The treatment of chronic idiopathic urticaria 
(CIU) is very difﬁcult. According Vena GA et al., 
cyclosporine (CsA) at a dosage of 5 mg/kg per 
day progressively reduced to 3 mg/kg per day 
in addition to background therapy with cetirizine 
during 8 weeks may be useful in the manage-
ment of CIU. This multicenter study included 99 
population recruited subjects in 18 Italian outpa-
tient clinics, all of them adult patients suffering 
from several relapsing CIU episodes. Exclusion 
criteria were other concomitant forms of urticaria, 
any contraindication to cetirizine and CsA (San-
dimum Neoral) and relevant systemic disorders. 
A a 1-week run-in period with cetirizine, 10 mg/
day, the patients entered a 16-week double-blind 
period of randomized treatment in addition to the 
background cetirizine therapy and were randomly 
allocated to one of three treatments: CsA for 16 
weeks; CsA for 8 weeks followed by placebo for 
8 weeks (8-week CsA), or placebo for 16 weeks. 
Sixty (60%) patients reported adverse events with 
fever in the placebo group (elevated serum creati-
nine increased in six patients receiving CsA). The 
Subject’s Global Assessment of relief of symptoms 
and Dermatology Life Quality Index (DLQI) over 
24-week post-randomization period proved the ef-
ﬁcacy and point change in total score at 16 and 
24 weeks. After 8 weeks, the severity score was 
signiﬁcantly improved by CsA with relief of symp-
toms and improvement in DLQI scores with CsA 
compared with placebo (1). This study conﬁrmed 
the clinical outcome in CIU with CsA as efﬁcient 
therapy at 8 weeks, as also reported by Grattan et 
al. (2), Cassano et al. (3), Poon et al. (4), Thomp-
son et al. (5), and Lennox and Leahy (6).
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 On the proposal of the National Health Coun-
cil, the Ministry of Health and Social Welfare of 
the Republic of Croatia issued a decision effec-
tive as of June 30, 2006, appointing the University 
Department of Dermatology and Venereology, Za-
greb University Hospital Center and Zagreb Uni-
versity School of Medicine, a Reference Center for 
Dermatologic Oncology of the Ministry of Health 
and Social Welfare (Reference Center for Derma-
tologic Oncology).
 In recent years, considerable progress has 
been made in dermatologic oncology. The inci-
dence of malignant skin tumors, melanoma in par-
ticular, then basal cell carcinoma and squamous 
cell carcinoma, has been on a constant increase 
worldwide, including Croatia. As Croatia is a Medi-
terranean country, this increasing trend poses a 
major public health problem. Thus, the Reference 
Center for Melanoma has already been estab-
lished at University Department of Dermatology 
and Venereology, Sestre milosrdnice University 
Hospital.
 The program of activities of the Reference Cen-
ter for Dermatologic Oncology includes numer-
ous actions in the ﬁeld of dermatologic oncology 
related to non-melanoma malignant tumors and 
primary skin lymphomas. Exact data on the inci-
dence of malignant epidermal tumors in Croatia 
are lacking; therefore, the Board on Dermatology 
and Venereology at Ministry of Health and Social 
Welfare has already established collaboration with 
the National Cancer Register. This collaboration 
has now been additionally encouraged and in-
cluded in the regular activities of the Reference 
Center for Dermatologic Oncology. Processing of 
data on malignant epidermal tumors in Croatia is 
under way. Data have been collected from reports 
submitted by dermatologists, ENT specialists, sur-
geons and other specialists treating patients with 
malignant epidermal tumors, with special refer-
ence to promotion of team approach in the diagno-
sis and treatment of malignant epidermal tumors 
and primary skin lymphomas.
 Attention will be especially focused on the ear-
ly diagnosis of malignant epidermal tumors as a 
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major factor inﬂuencing therapeutic outcome and 
patient’s quality of life. This can be successfully 
implemented at University Department of Derma-
tology and Venereology, Zagreb University Hospi-
tal Center, with properly equipped Laboratory of 
Skin Dermatologic Histopathology and Electron 
Microscopy Unit. Outpatient Clinic for Dermato-
logic Radiotherapy is part of the Reference Cen-
ter of Dermatologic Oncology. It is an appropriate 
therapeutic modality for elderly patients with ma-
lignant epidermal tumors, recurrent or inoperable 
malignant epidermal tumors, and some primary 
skin lymphomas, mycosis fungoides in particular.
 Photodynamic therapy as a treatment modality 
for precancerous lesions and some forms of basal 
cell carcinoma is also performed at the Center.
 Current diagnosis and treatment of primary 
skin lymphomas is an important segment of der-
matologic oncology. Clinical and histopathologic 
diagnosis has been developed at the Department 
for years, using a variety of modern methods of 
treatment for primary skin lymphomas. Efforts will 
be made to upgrade team approach in the ﬁeld, to 
the beneﬁt of our patients. 
 Nowadays, prevention of malignant skin tumors 
is an important task of every dermatologist/vene-
reologist. The program of the Reference Center 
includes prevention actions, which are focused on 
the respective education of the population at large, 
with special reference to young population groups, 
on the methods of protection from sunlight expo-
sure as a major factor in the etiology of malignant 
epidermal tumors. Special attention will be paid to 
secondary prevention, including early diagnosis 
and early therapy, which is closely associated with 
better prognosis.
 Another aspect of the Center activities is edu-
cation of dermatologists/venereologists in part 
serving their residency at the Reference Center 
for Dermatologic Oncology. In addition, mention 
should be made of the rich professional, scientiﬁc 
and publishing activities of the Center for Derma-
tologic Oncology.
Head Doctor Aida Pašić, MD, PhD
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 Upon the Ministry of Health and Social Wel-
fare of the Republic of Croatia decision effective 
as of June 30, 2006, University Department of 
Dermatology and Venereology, Zagreb University 
Hospital Center and Zagreb University School of 
Medicine, has been appointed Reference Center 
for Photodermatology of the Ministry of Health and 
Social Welfare, thus recognizing our Department 
as the leading institution in the ﬁeld of photoder-
matology in Croatia.
 Many new diagnostic and therapeutic modali-
ties in the ﬁeld of photodermatology, e.g., photo-
therapy, photochemotherapy, phototesting, photo-
dynamic therapy, and laser therapy, with the use 
of ultraviolet light (300-320 nm, 311±1 nm, 365 
nm), visible light (400-700 nm) and laser light of 
various wavelengths, have been employed at the 
Department. 
 Outpatient Clinic for Phototherapy was estab-
lished at University Department of Dermatology 
and Venereology in 1978, when the ﬁrst unit for 
UVB and UVA therapy was purchased. Since 
then, the development of photodermatology and 
photomedicine at the international level has been 
closely followed. These activities have been in-
tensiﬁed in the past decade. Currently, all modern 
phototherapy and photochemotherapy modalities, 
i.e. UVB, UVB 311 nm, UVA+UVB, PUVA, PUVA-
bath, phototherapy of palmoplantar dermatoses, 
and phototherapy in children, have been success-
fully applied at the Department.
 In 2003, the Unit for Laser in Corrective Der-
matology was established to provide treatment 
for almost all indications for the use of laser in 
dermatology/venereology. The most important 
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advantages of laser therapy over other methods 
of treatment include selective removal of skin le-
sions, excellent tolerability, short-term treatment 
and favorable cosmetic effects.
 In January 2004, local photodynamic therapy 
(PDT) was introduced at Department. PDT is a 
novel phototherapeutic modality that includes 
photochemical reactions with interaction of visible 
light, photosensitizing substances and oxygen. 
The aim of PDT is selective destruction of the tar-
get, abnormal cells while preserving normal ones.
Teaching activities for undergraduate students of 
the School of Medicine and postgraduate educa-
tion for physicians of various specialties have for 
years been performed at Outpatient Clinic for Pho-
totherapy. Work at Outpatient Clinic for Photother-
apy is part of residency in dermatology/venereol-
ogy. In addition, physicians and nurses working at 
phototherapy clinics established in Croatia to date 
have received respective training and education at 
our Department.
 Besides work with patients, attention has also 
been paid to professional and scientiﬁc activities 
in the ﬁeld of photodermatology.
 The newly established Reference Center for 
Photodermatology of the Ministry of Health and 
Social Welfare will invest all efforts to upgrade 
therapeutic and diagnostic methods in the ﬁeld of 
photodermatology, to continue providing education 
for professionals in the ﬁeld of photodermatology, 
to engage in professional and scientiﬁc activities, 
and to publish the results achieved.
Romana Čeović, MD, PhD
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